- Home
- ACCS vs HOWL Comparison
ACCS vs HOWL Comparison
Compare ACCS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | HOWL |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 30.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACCS | HOWL |
|---|---|---|
| Price | $7.01 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $5.00 |
| AVG Volume (30 Days) | 6.6K | ★ 482.0K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $8.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.48 | $0.50 |
| 52 Week High | $13.35 | $2.23 |
Technical Indicators
Market Signals| Indicator | ACCS | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 30.00 |
| Support Level | $6.77 | N/A |
| Resistance Level | $8.89 | $0.75 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 25.47 | 3.53 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.